SA521421375B1 - عمليات بديلة لتحضير مركبات تيوبولايسن ومركبات وسيطة منها - Google Patents

عمليات بديلة لتحضير مركبات تيوبولايسن ومركبات وسيطة منها

Info

Publication number
SA521421375B1
SA521421375B1 SA521421375A SA521421375A SA521421375B1 SA 521421375 B1 SA521421375 B1 SA 521421375B1 SA 521421375 A SA521421375 A SA 521421375A SA 521421375 A SA521421375 A SA 521421375A SA 521421375 B1 SA521421375 B1 SA 521421375B1
Authority
SA
Saudi Arabia
Prior art keywords
intermediates
preparation
tubulysins
alternative processes
tubulysin
Prior art date
Application number
SA521421375A
Other languages
English (en)
Inventor
وو كون-ليانج
جين كينجو
دوبليداي وينديل
Original Assignee
سياجن إنك.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by سياجن إنك. filed Critical سياجن إنك.
Publication of SA521421375B1 publication Critical patent/SA521421375B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يتعلق الاختراع الحالي بالكشف عن عمليات مُحسَّنة لتحضير مركبات تيوبولايسن tubulysin ومركبات رابط عقار تيوبولايسن tubulysin drug linker والمركبات الوسيطة منها.
SA521421375A 2018-09-07 2021-03-03 عمليات بديلة لتحضير مركبات تيوبولايسن ومركبات وسيطة منها SA521421375B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862728639P 2018-09-07 2018-09-07

Publications (1)

Publication Number Publication Date
SA521421375B1 true SA521421375B1 (ar) 2024-02-11

Family

ID=68000124

Family Applications (1)

Application Number Title Priority Date Filing Date
SA521421375A SA521421375B1 (ar) 2018-09-07 2021-03-03 عمليات بديلة لتحضير مركبات تيوبولايسن ومركبات وسيطة منها

Country Status (16)

Country Link
US (1) US20230002440A1 (ar)
EP (1) EP3847161A1 (ar)
JP (1) JP7511543B2 (ar)
KR (1) KR20210073525A (ar)
CN (1) CN112996778A (ar)
AU (1) AU2019336231A1 (ar)
BR (1) BR112021004317A2 (ar)
CA (1) CA3111149A1 (ar)
EA (1) EA202190699A1 (ar)
IL (1) IL281090A (ar)
MA (1) MA53550A (ar)
MX (1) MX2021002570A (ar)
SA (1) SA521421375B1 (ar)
SG (1) SG11202102126VA (ar)
TW (1) TWI825169B (ar)
WO (1) WO2020051503A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980833B2 (en) * 2007-05-10 2015-03-17 R&D-Biopharmaceuticals Gmbh Tubulysine derivatives
IT1394860B1 (it) * 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
CA3006000A1 (en) * 2015-12-04 2017-06-08 Seattle Genetics, Inc. Conjugates of quaternized tubulysin compounds
EA202090670A1 (ru) * 2017-09-08 2020-07-28 Сиэтл Дженетикс, Инк. Способ получения тубулизинов и их промежуточных соединений

Also Published As

Publication number Publication date
IL281090A (en) 2021-04-29
MX2021002570A (es) 2021-06-08
BR112021004317A2 (pt) 2021-05-25
WO2020051503A1 (en) 2020-03-12
US20230002440A1 (en) 2023-01-05
AU2019336231A1 (en) 2021-03-18
EP3847161A1 (en) 2021-07-14
CA3111149A1 (en) 2020-03-12
CN112996778A (zh) 2021-06-18
JP7511543B2 (ja) 2024-07-05
KR20210073525A (ko) 2021-06-18
SG11202102126VA (en) 2021-04-29
TW202024043A (zh) 2020-07-01
MA53550A (fr) 2021-12-15
JP2021536475A (ja) 2021-12-27
EA202190699A1 (ru) 2021-06-08
TWI825169B (zh) 2023-12-11

Similar Documents

Publication Publication Date Title
ZA202102696B (en) Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
PH12020551716A1 (en) Anti-ror antibody constructs
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX2016013999A (es) Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
MX2023002507A (es) Inhibidores de cd73.
MX2022002111A (es) Novedosos anticuerpos anti-cldn18.2.
WO2015164392A8 (en) Novel anti-rnf43 antibodies and methods of use
SG11201906435SA (en) Pyrimidine compound and pharmaceutical use thereof
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
MX2020011756A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2020001928A (es) Proceso para la preparacion de tubulisinas e intermediarios de las mismas.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
WO2015145449A3 (en) T-cell receptor cdr3 peptides and antibodies
WO2020123330A3 (en) Anti-alpha-synuclein antibodies and uses thereof
WO2018211324A8 (en) Prodrugs for the treatment of disease
SA521421375B1 (ar) عمليات بديلة لتحضير مركبات تيوبولايسن ومركبات وسيطة منها
MX2022007961A (es) Nuevos anticuerpos anti-fgfr2b.